Affordable Access

deepdyve-link
Publisher Website

Interim [18F] Fluorodeoxyglucose Positron Emission Tomography for early metabolic assessment of therapeutic response to chemotherapy for metastatic transitional cell carcinoma

Authors
  • Giannatempo, Patrizia
  • Alessi, Alessandra
  • Miceli, Rosalba
  • Raggi, Daniele
  • Farè, Elena
  • Nicolai, Nicola
  • Serafini, Gianluca
  • Padovano, Barbara
  • Piva, Luigi
  • Biasoni, Davide
  • Torelli, Tullio
  • Catanzaro, Mario
  • Stagni, Silvia
  • Maffezzini, Massimo
  • Mariani, Luigi
  • Gianni, Alessandro M.
  • Sonpavde, Guru
  • Salvioni, Roberto
  • Necchi, Andrea
  • Crippa, Flavio1, 2, 3, 2, 4, 2, 5, 6, 2, 7, 8
  • 1 Department of Medical Oncology
  • 2 Fondazione IRCCS Istituto Nazionale dei Tumori
  • 3 Nuclear Medicine and PET Unit
  • 4 Clinical Epidemiology and Trials Organization Unit
  • 5 Department of Surgery
  • 6 Urology Unit
  • 7 University of Milan School of Medicine
  • 8 UAB Comprehensive Cancer Center
Type
Published Article
Journal
Clinical Genitourinary Cancer
Publication Date
Jan 01, 2014
Accepted Date
Mar 11, 2014
Identifiers
DOI: 10.1016/j.clgc.2014.03.007
Source
Elsevier
Keywords
License
Unknown

Abstract

[18F]fluorodeoxyglucose positron emission tomography (FDG-PET) is increasingly used by many centers for staging and response assessment of metastatic transitional cell carcinoma (TCC). We prospectively evaluated 31 patients undergoing metabolic restaging after only 2 cycles of first-line chemotherapy (PET2). Early metabolic response was associated with patient outcome. The aim was to provide a proof-of-principle for a risk-adapted approach based on PET2 that may guide new trial design for early-recognized unresponsive patients.

Report this publication

Statistics

Seen <100 times